Our Resources | Association for Accessible Medicines

AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Oct 3, 2022 | Monét Stanford

Generics & Biosimilars Continue to Reward Patients, Employers and Taxpayers

October, 26, New Carrollton, MD

Sep 29, 2022 | Erica Klinger

October Can Now Afford to do More to Support Her Mental Health

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Susan Reilly

Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Erica Klinger

Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report

Avalere: New Analysis of Trends in Part D Generic Tiering, Pricing, and Patient Spending

Sep 15, 2022 | Susan Reilly

AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down

IQVIA White Paper: Pharmacy Discount Card Utilization and Impact

Sep 6, 2022 | Craig Burton

Explosive Growth in Drug Discount Cards is a Symptom of a Broken System

Video

Aug 23, 2022 | Erica Klinger

October's Story – Savings from Generic Medicines

Capitol Building - Washington D.C.

Aug 7, 2022 | Allen Goldberg

AAM Statement on Senate Passage of Inflation Reduction Act

AAM All Access Podcast

Jul 28, 2022 | Dan Leonard

AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients

David Gaugh at GRx+Biosims (North Bethesda, Maryland)

Jul 28, 2022 | Allen Goldberg

Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs

AAM Statement on H3

Jul 25, 2022 | Craig Burton

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

AAM All Access Podcast

Jul 21, 2022 | Dan Leonard

AAM All Access Podcast: CMMB’s Urgent Mission